Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
VAK694; Alutard Avanz SQ · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| VAK694 AND Immunotherapy (alutard) | EXPERIMENTAL | - |
| : VAK694 placebo AND Immunotherapy (alutard) | EXPERIMENTAL | - |
| VAK694 placebo AND Immunotherapy (alutard) placebo | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| VAK694; Alutard Avanz SQ | DRUG | - |
| VAK694 placebo infusion; Alutard Avanz SQ | DRUG | - |
| VAK694 placebo infusion; Saline | DRUG | - |
Inclusion Criteria: * History of atopy, defined as a history of seasonal allergic rhinitis for at least 2 years (in relation to the grass pollen allergy season), and evidence of atopy, defined as a positive skin prick test (wheal difference allergen - negative control at least 3 mm) to grass pollen...
VAK694 is an investigational small molecule being studied for the treatment of seasonal allergic rhinitis. It is being evaluated in combination with allergen immunotherapy to bring about specific immune tolerance. The drug is currently in Phase 2 clinical development and is not yet approved by regulatory authorities.
VAK694 is being developed by Novartis AG, a multinational pharmaceutical company traded on the New York Stock Exchange under the ticker symbol NVS. The drug is currently in Phase 2 clinical trials for seasonal allergic rhinitis.
VAK694 is in Phase 2 clinical development. It is an investigational drug for seasonal allergic rhinitis and has not been approved by the FDA or other regulatory agencies. One Phase 2 trial has been completed, and the drug remains under investigation.
VAK694 has one completed Phase 2 clinical trial registered as NCT01018693. This study, titled 'A Study to Determine the Capacity of VAK694 When Combined With Allergen Immunotherapy to Bring About Specific Immune Tolerance,' enrolled 37 participants with seasonal allergic rhinitis in the United Kingdom.
Yes, VAK694 is also known as Alutard Avanz SQ. Both names refer to the same investigational drug being developed by Novartis AG for seasonal allergic rhinitis. The drug is currently in Phase 2 clinical development.